Santarus reports GSK’s launch of Zegerid products

The Zegerid products were developed by Santarus and are the first and only immediate-release oral proton pump inhibitors (PPIs) commercialized in the US.
Zegerid (omeprazole/sodium bicarbonate) capsules and Zegerid powder for oral suspension are indicated for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease, maintenance of healing and short-term treatment of erosive esophagitis, and short-term treatment of active benign gastric ulcers and active duodenal ulcers. Zegerid powder for oral suspension 40mg is also indicated for the reduction of risk of upper gastrointestinal bleeding in critically ill patients.

Gerald Proehl, president and CEO of Santarus, said: “GSK has long demonstrated success in marketing products in the gastrointestinal therapeutic area, and we believe it is the ideal partner to bring physicians in these regions the message about the benefits of Zegerid products.”